William Blair Issues Positive Outlook for Harrow Earnings

Key Points

• William Blair has raised its Q1 2026 earnings estimate for Harrow, forecasting a loss of ($0.23) per share, an improvement from the previous estimate of ($0.27).
• Multiple analysts have given Harrow stock a strong "buy" rating, with target prices ranging from $64.00 to $70.00, indicating positive sentiment in the market.
• Harrow has a market capitalization of $1.78 billion and reported $63.74 million in revenue for its last quarter, beating consensus estimates.

Harrow, Inc. (NASDAQ:HROW - Free Report) - Equities research analysts at William Blair raised their Q1 2026 earnings estimates for shares of Harrow in a report released on Monday, September 29th. William Blair analyst L. Hanbury-Brown now forecasts that the company will post earnings of ($0.23) per share for the quarter, up from their previous forecast of ($0.27). William Blair has a "Outperform" rating on the stock. The consensus estimate for Harrow's current full-year earnings is ($0.53) per share.

Other analysts have also issued reports about the stock. B. Riley upped their price target on shares of Harrow from $65.00 to $70.00 and gave the stock a "buy" rating in a research report on Tuesday, September 23rd. HC Wainwright reaffirmed a "buy" rating and issued a $64.00 target price on shares of Harrow in a report on Monday. Lake Street Capital increased their price target on Harrow from $42.00 to $70.00 and gave the company a "buy" rating in a research note on Monday. Craig Hallum boosted their target price on shares of Harrow from $54.00 to $64.00 and gave the stock a "buy" rating in a report on Tuesday, September 23rd. Finally, BTIG Research restated a "buy" rating and set a $63.00 price objective on shares of Harrow in a research report on Wednesday, September 24th. Seven investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to MarketBeat.com, Harrow presently has an average rating of "Moderate Buy" and an average target price of $67.83.

Harrow Trading Down 0.5%

Shares of Harrow stock opened at $48.18 on Wednesday. The stock has a market cap of $1.78 billion, a P/E ratio of -192.72 and a beta of 0.33. The company has a quick ratio of 0.58, a current ratio of 0.62 and a debt-to-equity ratio of 0.78. Harrow has a 12-month low of $20.85 and a 12-month high of $59.23. The business's 50 day moving average is $38.94 and its 200-day moving average is $31.79.

Harrow (NASDAQ:HROW - Get Free Report) last released its earnings results on Monday, August 11th. The company reported $0.24 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.01 by $0.23. Harrow had a negative return on equity of 2.18% and a negative net margin of 4.49%.The business had revenue of $63.74 million for the quarter, compared to the consensus estimate of $64.23 million. Harrow has set its FY 2025 guidance at EPS.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in shares of Harrow by 89.5% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 61,940 shares of the company's stock valued at $2,078,000 after buying an additional 29,262 shares during the last quarter. GAMMA Investing LLC boosted its stake in Harrow by 2,401.2% during the 1st quarter. GAMMA Investing LLC now owns 6,278 shares of the company's stock valued at $1,670,000 after purchasing an additional 6,027 shares during the last quarter. Rhumbline Advisers boosted its stake in Harrow by 7.2% during the 1st quarter. Rhumbline Advisers now owns 42,975 shares of the company's stock valued at $1,143,000 after purchasing an additional 2,879 shares during the last quarter. Woodmont Investment Counsel LLC increased its holdings in Harrow by 27.4% during the 1st quarter. Woodmont Investment Counsel LLC now owns 103,693 shares of the company's stock worth $2,758,000 after purchasing an additional 22,293 shares in the last quarter. Finally, Westside Investment Management Inc. raised its stake in shares of Harrow by 6.3% in the first quarter. Westside Investment Management Inc. now owns 173,856 shares of the company's stock worth $4,625,000 after purchasing an additional 10,315 shares during the last quarter. Institutional investors and hedge funds own 72.76% of the company's stock.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.